Neuroscience Institute Named First Phinney Parkinson's Research Center
CINCINNATIThe Neuroscience Institute (TNI) at the University of Cincinnati (UC) and University Hospital today was named the first national Davis Phinney Research Center for Parkinsons disease.
As a national Davis Phinney Research Center, TNI is committed to collaborative laboratory research and the sharing of clinical data with new Davis Phinney centers at two other universities. The Denver-based Davis Phinney Foundation (DPF) will name its second national center later this month and a third before the end of the year.
Data sharing will spur competition and will propel us toward discovery of the very best practices and the very best treatments for Parkinsons patients, said John Tew, MD, chair of the DPFs Scientific Advisory Board, clinical director of TNI and professor of neurosurgery at the UC College of Medicine.
The Davis Phinney centers structure will serve as a model for the country, added Joseph Broderick, MD, vice chair of DPFs Scientific Advisory Board, research director of TNI and chair of neurology at UC. As a result of openness and collaboration, we predict that patient outcomes will improve at all the centers.
Data sharing between health centers is uncommon, Broderick said. We often do studies together academically, but intellectual property is not as easily shared. In addition, sharing treatment outcomes is not commonly done.
Cycling legend Davis Phinney, diagnosed with Parkinsons disease at age 40, established his foundation in Cincinnati in 2003 with the help of cycling enthusiasts Kathleen Krumme and David Ariosa. The foundation is devoted to improving the lives of people living with Parkinsons through collaborative research. It has invested nearly $250,000 in TNI through its signature fund-raising event, the Sunflower Revolution (www.sunflowerrev.org), a gala, auction, bike ride and educational symposium.
Phinney praised the institute for its excellence, its leadership and its willingness to embrace new ideas.
Cincinnatis researchers are working at the leading edge of Parkinsons treatment and research, he said. They have built extraordinary momentum during the last two years, and we expect them to play a national role in Parkinsons research.
Phinneys 300 national and international victories make him Americas winningest cyclist. He is one of only three Americans to win multiple stages of the Tour de France.
The Davis Phinney Foundation is dedicated to supporting research into the prevention and treatment of Parkinsons and to finding ways to improve the lives of people challenged by the disease.
The foundations national leadership council includes Lance Armstrong, the seven-time Tour de France champion, and Jeff Garvey, founding chairman of the Lance Armstrong Foundation.
The Neuroscience Institute, a regional center of excellence at the University of Cincinnati and University Hospital, is dedicated to patient care, research, education and the development of new treatments for stroke, brain and spinal tumors, epilepsy, multiple sclerosis, trauma, Parkinsons disease and Alzheimers disease.
The institutes Center for Parkinsons Disease and Movement Disorders is a regional referral center for patients in Greater Cincinnati and the surrounding four-state region. The center is currently engaged in 18 clinical trials, which include surgery, and numerous basic science research projects.
These include the study of the protective and restorative potential of neuregulins (growth factors involved in neurological functions), the accumulation of markers in brain cells as they degenerate with aging, side effects of standard medications, cellular and cell-signaling trophic factor replacement treatment, and embryonic development of cells lost in Parkinsons disease.
The center is affiliated with the UC Department of Neurology, ranked 10th nationally in NIH-sponsored research funding, and the Mayfield Clinic, which includes 22 neurosurgeons and sees 20,000 patients from a dozen countries and 35 states in a typical year.
Related Stories
Can new rules in Ohio address a pharmacy staffing shortage and...
May 17, 2024
The University of Cincinnati's Michael Hegener joined WVXU's Cincinnati Edition to discuss recent rules released by the Ohio Board of Pharmacy designed to address pharmacy staffing.
Is ketamine the answer to treatment-resistant depression?
May 16, 2024
The University of Cincinnati's Stephen Rush joined WVXU's Cincinnati Edition to discuss the use of ketamine and esketamine to treat treatment-resistant depression.
UC study: Severe ischemic strokes rare in total patient...
May 15, 2024
The University of Cincinnati’s Yasmin Aziz will present research at the European Stroke Organisation Conference that found severe ischemic strokes with the most severe damage are rare in the total stroke patient population.